The 2014 West African Ebola virus disease outbreak shocked the world as it swept through the region leaving Guinea, Liberia and Sierra Leone struggling to gain control. As the largest Ebola virus disease outbreak to date, there are more survivors in its wake than ever before, with a spectrum of health problems requiring management. Here we review various musculoskeletal manifestations of the virus that can occur both during and after the infection, and consider possible pathogenesis.
Introduction
In 2014, West Africa and the rest of the world were hit by a devastating outbreak of Ebola virus disease (EVD) that developed into a health crisis that left three countries gravely affected. The index case occurred in Guinea in late 2013; it quietly spread through nearby villages to reach neighbouring countries-Liberia and Sierra Leone-before spiralling out of control, being declared a 'Public Health Emergency of International Concern' by the WHO in August 2014 [1] . Travel-associated cases were reported in Nigeria, Mali and Senegal, and beyond Africa in the USA, UK, Italy and Spain [2, 3] . Although the peak of the epidemic was over by early 2015, sporadic cases persisted until April 2016; Guinea and Liberia were only declared free of transmission in June 2016 [4] , although the media and world's attention had long gone.
The first ever cases of EVD were identified 39 years ago in two concurrent outbreaks in rural villages in Sudan and near to the Ebola river of the Democratic Republic of the Congo, from where the name was coined. Various subtypes of the virus have caused many previous small, contained outbreaks in humans in Sudan, Uganda, Gabon, Republic of the Congo and Ivory Coast. The Reston Ebola virus strain has affected non-human primates in the Philippines [2, 5] . The West African outbreak was due to the Zaire strain, responsible for 17 of the 46 documented Ebola outbreaks [6] .
Virology and clinical features
Ebola virus belongs to the Filoviridae family; the natural host is the fruit bat. Zoonotic transmission to humans is through close contact with blood, secretions, organs or other bodily fluids of infected animals such as apes, antelopes and bats, often through consumption as bushmeat. Human-to-human spread can then occur, again through exposure to infected bodily fluids. Clinical manifestations of the illness may take from 2 to 21 days to appear, at which point the individual becomes highly infectious. Fever presents first, associated with fatigue, muscle pain, arthralgia, headache and sore throat. This is followed by vomiting, diarrhoea and rash. As the illness rapidly progresses, impaired kidney and liver function ensue and, in advanced cases, the hallmark internal and/or external haemorrhage occurs, although this was observed at lower frequency in the 2014 outbreak than previously. Other laboratory findings include low white blood cell and platelet counts [2, 5] . Also, rhabdomyolysis with an associated rise in creatinine kinase levels has been reported [7, 8] . The case fatality rate in the 2014 outbreak has been reported as 5070%, but has previously varied from 25 to 90% [2, 4] .
The 2014 outbreak
This recent pandemic has been catastrophic, affecting over 28 000 people and causing over 11 000 deaths, the largest ever outbreak by far [4] , with numerous reasons identified for its magnitude. Some of those highlighted are increased travel between villages and cities both in the affected countries and globally, plus local cultural practices, especially around burial traditions. More importantly, the ill-equipped healthcare infrastructure in the affected African countries struggled to cope with the overwhelming burden of prevention, treatment and surveillance.
During the height of the epidemic, the rapid rate of spread left very little response time. However, once good contact-tracing processes were in place and supportive care available, there was an improvement in the survival rates of EVD-infected patients. It is reported that somewhere in the range of 10 00015 000 survivors of the disease now exist in the region [3, 9] .
The question therefore arises: do we know enough about the long-term sequelae of EVD? Are rheumatic symptoms more than just simple complaints at the time of the acute illness? Research in EVD-infected patients and survivors to date reveals both acute and post-infectious complications. However, the true incidence remains unclear with the underlying pathogenesis largely hypothesized. In this review we focus on musculoskeletal involvement in EVD. A detailed literature search was conducted using PUBMED and published reports from the WHO and Centers for Disease Control and Prevention websites using the following search items: ebola, ebola virus, rheum*, arthr*, joint, complications, manifestations, longterm, sequelae, management.
Rheumatological manifestations
Experience from other infectious diseases demonstrates that rheumatological presentations and complications are relatively common both acutely and in convalescence. While most viral arthritides present as a transient, selflimiting, non-erosive polyarthritis, some can persist for months and in some cases become chronic. Notable examples are parvovirus B19 infection, where up to 60% of adult women experience joint involvement, with a fifth affected for many months. Also, with alphaviruses such as Chikungunya, arthralgia and arthritis are being increasingly recognized as post-infectious complications, affecting up to 50% of patients at 3 years and about 10% at 5 years [1012] .
In the acute phase of EVD, arthralgia and myalgia are common [8] , although symptoms can be non-specific. Lado et al. reported 18 and 22% incidence of joint and muscle pain, respectively, from Ebola patients presenting to Connaught Hospital, Sierra Leone. However, in an early follow-up study of survivors in the first 3 weeks after discharge in Freetown, Scott et al. found 70% to have either or both complaints, though localization or characterization remained unspecified or generalized [1316] . Further description of the pattern of muscle and joint involvement in the acute phase of illness is sparse in published literature. Given the multi-organ manifestations of the disease, it is understandable that investigation of acute infection has focused on other potentially lifesaving aspects of assessment and care.
The longer term musculoskeletal complications post-EVD are varied, including muscle pain and weakness, arthritis, enthesitis and tendon ruptures. In a study by Rowe et al. [17] 
In addition to other symptoms, the survivors had increased risk of ongoing arthralgia mainly in the large joints (risk ratio (RR) = 2.0, 95% CI: 1.13.6; P = 0.020) and muscle pain (RR = 2.5, 95% CI: 1.05.9; P = 0.040), which was significant in the sensitivity analysis comparing seropositive survivors to all seronegative contacts [18] . Data from the West Africa outbreak so far suggest that arthralgia is one of the most frequent post-infectious sequelae, observed in 76, 77.7 and 86.7% of survivors in three cohort studies totalling 548 patients, with mean time to first follow-up of 121, 51.1 and 103.5 days [16, 19, 20] .
Observations indicate a pattern of arthralgia that is typically symmetrical involving multiple joints, most frequently affecting knees, back, hips, small joints of the hand, wrists, neck, shoulders, ankles and elbows. There is a mixed picture of early morning stiffness; however, joint pain has also been noted to worsen with activity. Enthesitis has been reported in the hip joint associated with a spondyloarthritis, particularly when inflammatory eye disease is present [15] . Clinical examination rarely demonstrates joint swelling, redness or warmth, although tenderness may sometimes be elicited. Functional limitation is often absent and corresponding X-rays are normal [16, 17, 19] .
There have been very few cases of active synovitis noted in the literature. An EVD survivor, in a follow-up clinic of 166 survivors in Freetown, Sierra Leone, presented with a proximal IP joint effusion of the left hand without previous history of trauma or rheumatic disease. No changes on X-ray were noted. Joint swelling was present for 3 weeks and resolved with empiric antibiotic treatment [16] . Another report details monoarthritis of a knee joint in a survivor 34 days after disease onset. SF was aspirated and found to be negative for virus isolation by RT-PCR [21] .
During the height of the infection, trials were set up to investigate the response to potential Ebola virus vaccines.
www.rheumatology.oxfordjournals.org Several clinical events were reported, including vaccineinduced arthritis. In a phase 1 trial of replication-competent recombinant vesicular stomatitis virus-based vaccine expressing a Zaire-Ebola virus glycoprotein, confirmed musculoskeletal involvement was found in 11 out of 51 (22%) participants in one trial centre. This included arthralgia, inflammatory arthritis, tendinitis and bursitis. Typically, participants presented with a mild oligoarthritis pattern and mild to moderate functional limitation. Median onset was 11 days (interquartile range: 913 days) after injection and symptoms were generally self-limiting (median duration 8 days; interquartile range: 487 days). At 6-month review 10 out of the 11 participants were asymptomatic. Synovial aspirate from one participant showed presence of recombinant vesicular stomatitis virus on PCR assay, but viral and bacterial cultures of both SF and blood were negative [21] .
Pathogenesis
Acutely and longer term, musculoskeletal complications appear to be both common and significant and cannot be ignored. The mechanisms postulated are similar to those for other viral arthritides, including tissue damage due to direct viral effects, such as the release of pro-inflammatory cytokines from virus-infected cells, and production of autoantibodies, such as RF [10] . In the first instance Ebola virus antibodies are present and can persist for several months; it is uncertain whether the antibody titre levels predict the severity of health problems. In Rowe's study, it was noted that Zaire-Ebola virus specific antibody concentration was higher in survivors reporting arthralgia than in survivors without arthralgia [17] . Certainly, arthritis from parvovirus and rubella is associated with the development of antibodies, so a similar immunological mechanism is plausible [22] ; however, reports so far have not shown the presence of autoantibodies [23, 24] .
Although there is little research into detection of virus in affected joints, Ebola virus RNA has been detected in various so called 'immune privileged sites' of the body with a range of clinical sequelae. Ebola RNA has been found in semen for several months post-infection and is thought to have been the route of transmission during the recent resurgence of infection in Liberia [2] . Ebola RNA has also been found in ocular fluid up to 3 months after acute infection and has been associated with uveitis during convalescence [25] . More recently, both CSF and peripheral blood were found positive for Ebola RNA in a patient presenting with meningitis over 9 months after recovery from initial infection. A case of encephalitis and polyarthritis following viral RNA clearance from blood has also been described [21, 26] . These complications raise huge concern about viral persistence and late re-emergence in other body sites. Long term data are lacking about the presence of Ebola virus within SF [27, 28] and certainly whether its presence in joints and soft tissue may contribute to the high rates of musculoskeletal complaints.
Though rheumatological manifestations may be present, lasting or damaging arthritis does not so far appear to be a feature of EVD. One further point to explore with the high prevalence of musculoskeletal complaints is the huge psychological burden of disease and its impact on physical well-being and symptoms. We know there is a relationship between pain conditions and generalized anxiety disorders, which are common in the general population [29] . Given the many distressing sights and experiences that EVD imposes on those affected, it is unsurprising that psychological complaints are highly prevalent, having been described in previous outbreaks as well as the 2014 outbreak [18, 20, 30] . A post-Ebola syndrome has been described in survivors, who present with headaches, traumatic flashbacks, visual complaints, hair loss, impaired hearing, extreme fatigue, insomnia, memory loss and anxiety attacks. It therefore seems plausible that this syndrome could contribute to the pain syndromes that survivors experience.
Conclusion
Overall, emerging evidence suggests that even for the more fortunate who survive the acute infection, the disease has still not run its course. With the large number of survivors from the West Africa outbreak, there is a valuable cohort to follow up and undertake research to determine longer term outcomes and clinical effects, already seen in a substantial proportion.
Seemingly, the threat to the rest of the world may be gone, but we must not forget the burden of problems that continue to face those most affected. The Ebola virus epidemic has been one of the most challenging global public health emergencies in recent times. For survivors, the aftermath is plagued by chronic health problems, which may be present over 2 years following infection. Survivors' stories tell the tale of challenges returning to work to earn a living because of debilitating joint symptoms among others. There is an ongoing need for healthcare resources, and much work is still needed to decrease the ongoing stigma of this disease, plus its impact on economic and social livelihood.
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